Literature DB >> 8374872

Antigenic stimulation and multiple myeloma. A prospective study.

C C Bourguet1, E E Logue.   

Abstract

BACKGROUND: A causal relationship between antigenic conditions and multiple myeloma was suggested by case reports. Although controlled studies identified associations with individual conditions, they failed to give overall support to the hypothesis. Using a prospective cohort representative of the U.S. population, the authors hypothesized that immune-stimulating conditions are a risk factor for multiple myeloma.
METHODS: The First National Health and Nutrition Examination Survey cohort of 14,407 persons were interviewed from 1971 to 1975 by the National Center for Health Statistics. Vital status with cause of death and hospitalizations were ascertained from 1982 to 1985 and in 1986. From the initial questionnaire, four risk factors were constructed: allergies (asthma, hives, hay fever, food allergies, and other allergies); autoimmune conditions (arthritis, thyroid disease and/or medication, rheumatic fever, diabetes, pernicious anemia); chronic bacterial conditions (chronic bronchitis or emphysema, chronic cough, tuberculosis, ulcers); and inflammatory conditions (gout, gallstones, recurrent or chronic enteritis, pleurisy).
RESULTS: Eighteen multiple myeloma (MM) cases were documented. The rate ratio (RR) of MM increased as the number of reported inflammatory conditions increased (one condition, RR = 2.0, 95% confidence interval [CI] = 1.2-3.3; 2 or more conditions, RR = 4.3, 95% CI = 1.5-12.4). The RR of myeloma also increased (P = 0.0002) with time since start of inflammatory conditions (RR = 1.6 for every 10 years of exposure). When cases were restricted to those with more than five years of follow-up, myeloma risk increased with the number of inflammatory conditions (two conditions, RR = 4.6, 95% CI = 1.5-13.8).
CONCLUSIONS: Although the number of cases is small and exposure may be misclassified, the prospective nature of the study design strengthens the results of the study.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8374872     DOI: 10.1002/1097-0142(19931001)72:7<2148::aid-cncr2820720714>3.0.co;2-q

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  6 in total

1.  Primary sclerosing cholangitis in association with multiple myeloma.

Authors:  Nasrollah Ahmadpour; Matthew Downey; Elizabeth Frauenhoffer; Thomas Riley; Ian R Schreibman
Journal:  Gastroenterol Hepatol (N Y)       Date:  2008-08

Review 2.  TGF- β: an important mediator of allergic disease and a molecule with dual activity in cancer development.

Authors:  Belen Tirado-Rodriguez; Enrique Ortega; Patricia Segura-Medina; Sara Huerta-Yepez
Journal:  J Immunol Res       Date:  2014-06-11       Impact factor: 4.818

3.  Multiple myeloma and atopic eczema in an adult.

Authors:  Mohammad Amir Hossain; Qiang Nai; Ping Zhang; Hongxiu Luo; Mohammed Amzad Hossain; Abdul Mahmad; Abdalla M Yousif; Shuvendu Sen
Journal:  Case Rep Oncol       Date:  2015-02-06

Review 4.  Aspirin and risk of multiple myeloma in adults: A systematic review and meta-analysis.

Authors:  Shing Fung Lee; Ting Ying Ng; Frank Chi Sing Wong; Stewart Yuk Tung
Journal:  Leuk Res Rep       Date:  2017-02-28

5.  Allergic disease, corticosteroid use, and risk of Hodgkin lymphoma: A United Kingdom nationwide case-control study.

Authors:  Meena Rafiq; Andrew Hayward; Charlotte Warren-Gash; Spiros Denaxas; Arturo Gonzalez-Izquierdo; Georgios Lyratzopoulos; Sara Thomas
Journal:  J Allergy Clin Immunol       Date:  2019-11-12       Impact factor: 10.793

6.  Risk of multiple myeloma in rheumatoid arthritis: a meta-analysis of case-control and cohort studies.

Authors:  Kaini Shen; Gufeng Xu; Qing Wu; Daobin Zhou; Jian Li
Journal:  PLoS One       Date:  2014-03-13       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.